Clinical data | |
---|---|
Pronunciation | spar FLOX a sin |
Trade names | Spacin, Zagam, others |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a600002 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 92% |
Protein binding | 45% |
Metabolism | Hepatic glucuronidation Cytochrome P450 system not involved |
Elimination half-life | 16 to 30 hours |
Excretion | Fecal (50%) and renal (50%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.157.238 |
Chemical and physical data | |
Formula | C19H22F2N4O3 |
Molar mass | 392.407 g·mol−1 |
3D model (JSmol) | |
Melting point | 266 to 269 °C (511 to 516 °F) (dec.) |
| |
| |
(verify) |
Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile.[1]
It was patented in 1985 and approved for medical use in 1993.[2] Zagam is no longer available in the United States.